15018-50-5

Basic information

• Product Name: 1-phenylpyrimidine-2,4,6(1H,3H,5H)-trione
• Synonyms: 2,4,6(1H,3H,5H)-pyrimidinetrione, 1-phenyl-
• CAS NO: 15018-50-5
• Molecular Formula: C₁₀H₈N₂O₃
• Molecular Weight: 204.1821
• Mol File: 15018-50-5.mol
• Article Data: 12

Chemical Properties

• Density: 1.386g/cm³
• Refractive Index: 1.597
• CAS DataBase Reference: 1-phenylpyrimidine-2,4,6(1H,3H,5H)-trione(CAS DataBase Reference)
• NIST Chemistry Reference: 1-phenylpyrimidine-2,4,6(1H,3H,5H)-trione(15018-50-5)
• EPA Substance Registry System: 1-phenylpyrimidine-2,4,6(1H,3H,5H)-trione(15018-50-5)

Safety Data

• Hazardous Substances Data: 15018-50-5(Hazardous Substances Data)

Usage

General Description

1-phenylpyrimidine-2,4,6(1H,3H,5H)-trione, also known as phenylbarbitone, is a chemical compound belonging to the class of barbiturates. It is a white, odorless, crystalline powder with sedative and hypnotic properties. 1-phenylpyrimidine-2,4,6(1H,3H,5H)-trione is commonly used in medicine as a central nervous system depressant to treat insomnia, anxiety, and epilepsy. It works by enhancing the activity of the neurotransmitter GABA in the brain, leading to a calming and sedative effect. However, 1-phenylpyrimidine-2,4,6(1H,3H,5H)-trione can also be addictive and has a high potential for misuse and dependence. Therefore, it is considered a controlled substance and should only be used under the guidance of a healthcare professional.

Upstream product

• 141-82-2 malonic acid 
• 64-10-8 phenyl carbamate 
• 105-53-3 diethyl malonate 
• 62-53-3 aniline 
• 108-59-8 malonic acid dimethyl ester 
• 77-78-1 dimethyl sulfate 
• 15837-45-3 6-amino-1-phenyluracil 

Downstream Products

• 94212-33-6 5-((Ξ)-trans-cinnamylidene)-1-phenyl-barbituric acid 
• 91974-06-0 5-acetyl-1-phenyl-pyrimidine-2,4,6-trione 
• 68160-64-5 5-benzylidene-1-phenyl-pyrimidine-2,4,6-trione 
• 70450-58-7 5-anilinomethylene-1-phenyl-pyrimidine-2,4,6-trione 
• 61753-92-2 5-amino-1-phenyl-barbituric acid 
• 90767-12-7 1-phenyl-5-Bromobarbituric acid 
• 82628-28-2 1-phenylvioluric acid 
• 90948-22-4 5,5-dibromo-1-phenylbarbituric acid 
• 102-03-4 1-acetyl-3-phenylurea 
• 128226-15-3 C₂₂H₁₅N₅O₄ 
• 128226-10-8 C₂₁H₁₂FN₅O₄ 
• 128226-12-0 C₂₁H₁₂FN₅O₄ 
• 128226-16-4 C₂₃H₁₅N₅O₅ 
• 128226-11-9 C₂₃H₁₇FN₄O₆ 

Relevant articles and documents

Selective cell adhesion inhibitors: Barbituric acid based α4β7-MAdCAM inhibitors

A novel series of barbituric acid derivatives were identified as selective inhibitors of α4β7 MAdCAM (mucosal addressin cell adhesion molecule-1) interactions via a high throughput screening exercise. These inhibitors were optimized to submicromolar potencies in whole cell adhesion assays, retaining their selectivity over α4β1 VCAM.

Pyrimidones including six hydrogens quinoline compound and its preparation method and application

The invention relates to a quinolines compound containing hexahydropyrimidone, which is represented by a formula I, as well as pharmaceutically acceptable configurational isomers, salts, hydrates, solvates and prodrugs thereof. According to the quinolines compound, substituent groups R1, R2, R3, X, Y, Z and n have definitions given in the specification. The invention further relates to the compound of the formula I and the configurational isomers which have a very strong effect of inhibiting c-Met kinase, further relates to an application of the compounds and the pharmaceutically acceptable salts, hydrates, solvates or prodrugs in preparing a medicine for treating diseases caused by hydrates high expression of the c-Met kinase, and particularly relates to an application of a medicine for preparing a medicine for treating and/or preventing cancers.

Discovery of novel 6,7-disubstituted-4-phenoxyquinoline derivatives bearing 5-(aminomethylene)pyrimidine-2,4,6-trione moiety as c-Met kinase inhibitors

A series of novel quinoline derivatives bearing 5-(aminomethylene) pyrimidine-2,4,6-trione moiety were designed, synthesized, and evaluated for their c-Met kinase inhibitory activities and antiproliferative activities against 5 cancer cell lines (HT-29, H460, MKN-45, A549, and U87MG) in vitro. Most compounds showed moderate to excellent potency, with the most promising analogue 45 (c-Met half-maximal inhibitory concentration [IC50] = 1.15 nM) showing high selectivity versus 5 other tyrosine kinases, VEGFR-2, Flt-3, PDGFR-β, c-Kit, and EGFR. Structure-activity relationship studies indicated that electron-donating groups on the phenyl ring at the 3-position of pyrimidine-2,4,6-trione were required to increase the electron density on the 5-(aminomethylene)pyrimidine-2,4,6-trione moiety.